A Phase 1, Dose Escalation Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma

Trial Profile

A Phase 1, Dose Escalation Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs ALX 148 (Primary) ; Atezolizumab (Primary) ; Trastuzumab (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Alexo Therapeutics
  • Most Recent Events

    • 10 Nov 2017 According to an Alexo Therapeutics media release, preliminary data were presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
    • 24 Oct 2017 Planned number of patients changed from 110 to 142.
    • 05 Oct 2017 According to an Alexo Therapeutics media release, data will be presented at the SITC 32nd Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top